Developer docs
API playgroundTry for free, no card

Search company profiles

Light AI

Full company profile

uuid0002ega

Namestring
Light AI
Legal namestring
Light AI Inc.
Websiteurl
light.ai
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Light AI Inc. (Cboe Canada: ALGO; OTCQB: OHCFF; FSE: 0HC) is a Vancouver-based, publicly traded medical imaging software company developing AI-driven diagnostic tools that analyze standard smartphone camera images to detect infectious diseases without swabs, lab reagents, or proprietary hardware. Its flagship product, QuickScan Strep A, is a cloud-based computer vision application that classifies oropharyngeal images as bacterial (Group A Streptococcus) or viral, with pre-FDA validation studies reporting 96.57% accuracy and 100% Negative Predictive Value; the underlying algorithms are protected by 7 granted patents across the US, Europe, Australia, and Israel. The company's product portfolio centers on the QuickScan Strep A Software as a Medical Device, a direct-to-consumer Wellness App (planned Q3 2025 launch for Strep A, COVID-19, and conjunctivitis), and the Light AI Digital Clinical Lab cloud platform with a stated roadmap toward eye and skin conditions.

The business is in clinical and regulatory development rather than commercial operation. QuickScan Strep A is in an FDA pivotal trial initiated June 2026 with Health Canada registration submitted and an ISO 13485/QMS audit in progress; Light AI explicitly states that its products are not cleared or approved and not available for commercial or clinical use. Planned monetization includes subscription pricing for the consumer Wellness App, licensing of the diagnostic platform to healthcare providers and clinical institutions, and international rollout tied to FDA, Health Canada, and European regulatory authorizations. Pilot deployments exist with the National Hauora Coalition in New Zealand and an unnamed global urgent-care provider, and a partnership with MrBeast/Beast Philanthropy is aimed at deploying AI-powered Strep A testing in Africa for rheumatic heart disease prevention.

Operationally, Light AI had 11–50 employees, was founded by Peter Whitehead (inventor of the VELscope oral cancer imaging device, now Chief Innovation Officer), and is led by CEO John R. Luna (appointed January 2026) to drive regulatory and commercialization execution. Capital structure reflects an early-stage profile: a C$18.5M Canadian IPO in January 2025, a C$5M convertible debenture in May 2025, a US$5M MV Capital private placement in June 2026, and an additional C$5M debenture that month, supporting stated cash runway beyond Q3 2026 against widening operating losses.

Short descriptiontext

Light AI is a Vancouver-based medical imaging software company using proprietary AI to analyze smartphone images and detect Strep A, COVID-19, and conjunctivitis without swabs or proprietary hardware, targeting healthcare providers and consumers via QuickScan and a planned Wellness App.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI medical diagnostics, infectious disease detection, smartphone health screening, computer vision diagnostics, point-of-care testing
Industry2 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI Medical Diagnostics Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Wellness App Sales
TypeSubscription Recurring
Description

Direct-to-consumer sales of AI-powered health diagnostic wellness application for detecting Strep A, COVID-19, and conjunctivitis. Expected to launch commercially in North America in Q3 2025 with subsequent global expansion.

light.ai
2Healthcare Provider Licensing
TypeLicensing Royalties
Description

Licensing agreements with healthcare providers and clinical institutions for use of the diagnostic platform. Pilot studies with global healthcare providers planned to validate clinical performance.

light.ai
3International Regulatory Authorization
TypeSubscription Recurring
Description

Revenue generation following regulatory approvals (FDA, Health Canada, European certifications) enabling commercialization in respective jurisdictions. Consumer-facing Wellness App anticipated in North America by Q3 2025; European launch planned.

light.ai
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Consumer Wellness App (direct-to-consumer)
ModelSubscriptionBilling cadenceMonthly
Notes

Wellness App for consumer health screening of Strep A, COVID-19, and conjunctivitis. Pricing not publicly disclosed as product is in pre-commercialization stage.

light.ai
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 2 records shown
1QuickScan™ Strep A
Description

AI-powered diagnostic software that analyzes smartphone images to detect Group A Streptococcus (Strep A) infections.

light.ai
+1 more record
Core offering1 text field

Light AI develops AI-powered diagnostic software that applies machine learning algorithms to smartphone camera images to identify bacterial and viral infections in seconds. The company offers two distinct products: QuickScan Strep A, a clinical diagnostic software for healthcare providers to differentiate Group A Streptococcus infections at point-of-care, and a consumer-facing Wellness App for at-home screening of Strep A, COVID-19, and conjunctivitis. The cloud-based platform requires no swabs, lab tests, or proprietary hardware, leveraging the 4.5 billion existing smartphones globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 97% accuracy in differentiating viral vs bacterial pharyngitis (96.57% in some studies)
+4 more records
Product overview1 text field

Light AI offers an AI-powered diagnostic platform consisting of QuickScan Strep A (clinical diagnostic software) and a consumer-facing Wellness App. Both products use the same core cloud-based AI technology that applies proprietary computer vision algorithms to smartphone camera images to identify medical conditions. The platform requires no hardware beyond a standard smartphone and targets point-of-care diagnostics for infectious diseases starting with Strep A pharyngitis, with expansion to COVID-19 and conjunctivitis.

Product and service3 records
1QuickScan Strep A
CategoryClinical Diagnostic Software
Description

AI-powered diagnostic software that analyzes smartphone images of the oropharynx to identify Group A Streptococcus (Strep A) infections at point-of-care. Designed for healthcare providers to differentiate between viral and bacterial pharyngitis, achieving 96.57% accuracy and 100% NPV in pre-FDA validation studies.

2Light AI Wellness App
CategoryConsumer Health Application
Description

Direct-to-consumer mobile application for at-home health screening of Strep A, COVID-19, and conjunctivitis using AI algorithms applied to smartphone camera images. Targets families and individuals for home health management without requiring swabs, lab tests, or proprietary hardware.

3Light AI Digital Clinical Lab Platform
CategoryCloud Diagnostic Platform
Description

Cloud-based AI platform vision combining smartphone cameras with cloud AI to provide quick and accessible diagnosis for multiple conditions. Currently focused on throat conditions, with expansion planned for eye (conjunctivitis) and skin analysis. Requires no swabs, lab tests, or proprietary hardware.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-15
Description

Pilot study partnership with National Hauora Coalition New Zealand for QuickScan Strep A testing in New Zealand healthcare settings to validate clinical performance.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-02-19
Description

Partnership with ELIQUENT Life Sciences to support bringing Light AI's cutting-edge AI medical technologies to the U.S. market. ELIQUENT provides regulatory consulting and submission support for FDA authorization process.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-02-18
Description

High-profile partnership to provide AI-powered Strep A testing in Africa. Beast Philanthropy (MrBeast's philanthropic organization) collaborating to deploy Light AI's diagnostic technology in underserved regions for rheumatic heart disease prevention.

4Commodity Partners Inc.
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-02-14
Description

Engagement of investor relations services from Commodity Partners Inc. to provide capital markets and investor relations advisory services under agreement dated February 14, 2025 for CDN$120,000 annual fee.

light.ai
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-02-07
Description

Engagement with Emergo by UL for global regulatory submissions support. Provides regulatory consulting services for international market authorization beyond U.S. FDA process.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthy.io uses smartphone cameras combined with AI/computer vision to enable at-home urinalysis and chronic kidney disease screening—closely paralleling Light AI's smartphone-camera AI diagnostic model and regulatory pathway.

TypeDirect peer
Description

TytoCare delivers AI-assisted remote physical examination and diagnostics via consumer devices for telehealth providers—comparable in delivering AI-enhanced clinical assessments through consumer-grade hardware at the point of care.

TypeDirect peer
Description

Visby Medical develops rapid PCR-based diagnostic tests for infectious diseases including sexual health and respiratory infections—directly competing in the point-of-care infectious disease diagnostic market that Light AI is targeting with QuickScan Strep A.

4Cue Health
TypeDirect peer
Description

Cue Health produces a connected rapid molecular diagnostic platform for at-home and clinical use, including respiratory infections (COVID-19, influenza)—a direct competitor in consumer/clinical rapid infectious disease diagnostics.

TypeDirect peer
Description

ResApp Health developed AI algorithms to diagnose respiratory conditions (pneumonia, bronchiolitis, COPD) from cough and lung sound recordings—a highly comparable AI-audio/visual diagnostic platform for infectious disease (acquired by Pfizer in 2022).

TypeDirect peer
Description

Eko Health combines AI with digital stethoscopes and sensors to detect cardiac and pulmonary conditions—closely parallel to Light AI's model of applying AI to standard hardware for clinical-grade diagnosis.

TypeDirect peer
Description

Binx Health provides rapid molecular diagnostics for infectious diseases at point-of-care, including CT/NG testing—directly comparable to Light AI's goal of decentralizing infectious disease testing away from centralized labs.

8Babylon Health
TypeBroad incumbent
Description

Babylon Health offers a broader AI-driven symptom assessment and triage platform that competes at the diagnostic decision-support layer Light AI targets—though Babylon is a wider digital health incumbent rather than a focused infectious-disease specialist.

9K Health
TypeEmerging player
Description

K Health combines AI symptom checking with telehealth consultations to deliver remote diagnoses—a comparable AI-driven consumer health diagnostic experience, though focused on primary care rather than specific infectious disease imaging.

TypeEmerging player
Description

DreaMed developed AI clinical decision support for diabetes management—an adjacent regulated SaMD player demonstrating the AI clinical decision support pathway Light AI is pursuing, though in a different therapeutic area.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Light AI

AI Medical Diagnostics Softwarelight.ai

Light AI is a Vancouver-based medical imaging software company using proprietary AI to analyze smartphone images and detect Strep A, COVID-19, and conjunctivitis without swabs or proprietary hardware, targeting healthcare providers and consumers via QuickScan and a planned Wellness App.

What Light AI does

Light AI Inc. (Cboe Canada: ALGO; OTCQB: OHCFF; FSE: 0HC) is a Vancouver-based, publicly traded medical imaging software company developing AI-driven diagnostic tools that analyze standard smartphone camera images to detect infectious diseases without swabs, lab reagents, or proprietary hardware. Its flagship product, QuickScan Strep A, is a cloud-based computer vision application that classifies oropharyngeal images as bacterial (Group A Streptococcus) or viral, with pre-FDA validation studies reporting 96.57% accuracy and 100% Negative Predictive Value; the underlying algorithms are protected by 7 granted patents across the US, Europe, Australia, and Israel. The company's product portfolio centers on the QuickScan Strep A Software as a Medical Device, a direct-to-consumer Wellness App (planned Q3 2025 launch for Strep A, COVID-19, and conjunctivitis), and the Light AI Digital Clinical Lab cloud platform with a stated roadmap toward eye and skin conditions.

The business is in clinical and regulatory development rather than commercial operation. QuickScan Strep A is in an FDA pivotal trial initiated June 2026 with Health Canada registration submitted and an ISO 13485/QMS audit in progress; Light AI explicitly states that its products are not cleared or approved and not available for commercial or clinical use. Planned monetization includes subscription pricing for the consumer Wellness App, licensing of the diagnostic platform to healthcare providers and clinical institutions, and international rollout tied to FDA, Health Canada, and European regulatory authorizations. Pilot deployments exist with the National Hauora Coalition in New Zealand and an unnamed global urgent-care provider, and a partnership with MrBeast/Beast Philanthropy is aimed at deploying AI-powered Strep A testing in Africa for rheumatic heart disease prevention.

Operationally, Light AI had 11–50 employees, was founded by Peter Whitehead (inventor of the VELscope oral cancer imaging device, now Chief Innovation Officer), and is led by CEO John R. Luna (appointed January 2026) to drive regulatory and commercialization execution. Capital structure reflects an early-stage profile: a C$18.5M Canadian IPO in January 2025, a C$5M convertible debenture in May 2025, a US$5M MV Capital private placement in June 2026, and an additional C$5M debenture that month, supporting stated cash runway beyond Q3 2026 against widening operating losses.

Light AI firmographics

Firmographics
Name
Light AI
Legal name
Light AI Inc.
Website
https://light.ai
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Light AI is a Vancouver-based medical imaging software company using proprietary AI to analyze smartphone images and detect Strep A, COVID-19, and conjunctivitis without swabs or proprietary hardware, targeting healthcare providers and consumers via QuickScan and a planned Wellness App.
Ownership category
akta.pro rank

Light AI industry classification

Industry
Product category
AI Medical Diagnostics Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • AI medical diagnostics
  • Infectious disease detection
  • Smartphone health screening
  • Computer vision diagnostics
  • Point-of-care testing

Where Light AI is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Light AI business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Wellness App Sales: Direct-to-consumer sales of AI-powered health diagnostic wellness application for detecting Strep A, COVID-19, and conjunctivitis. Expected to launch commercially in North America in Q3 2025 with subsequent global expansion.
  2. Healthcare Provider Licensing: Licensing agreements with healthcare providers and clinical institutions for use of the diagnostic platform. Pilot studies with global healthcare providers planned to validate clinical performance.
  3. International Regulatory Authorization: Revenue generation following regulatory approvals (FDA, Health Canada, European certifications) enabling commercialization in respective jurisdictions. Consumer-facing Wellness App anticipated in North America by Q3 2025; European launch planned.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyConsumer Wellness App (direct-to-consumer)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Light AI product offering

Product offering

Core offering

Light AI develops AI-powered diagnostic software that applies machine learning algorithms to smartphone camera images to identify bacterial and viral infections in seconds. The company offers two distinct products: QuickScan Strep A, a clinical diagnostic software for healthcare providers to differentiate Group A Streptococcus infections at point-of-care, and a consumer-facing Wellness App for at-home screening of Strep A, COVID-19, and conjunctivitis. The cloud-based platform requires no swabs, lab tests, or proprietary hardware, leveraging the 4.5 billion existing smartphones globally.

Product overview

Light AI offers an AI-powered diagnostic platform consisting of QuickScan Strep A (clinical diagnostic software) and a consumer-facing Wellness App. Both products use the same core cloud-based AI technology that applies proprietary computer vision algorithms to smartphone camera images to identify medical conditions. The platform requires no hardware beyond a standard smartphone and targets point-of-care diagnostics for infectious diseases starting with Strep A pharyngitis, with expansion to COVID-19 and conjunctivitis.

Differentiator

Problem solved

Functional benefit

Brands

  • QuickScan™ Strep A: AI-powered diagnostic software that analyzes smartphone images to detect Group A Streptococcus (Strep A) infections.
  • Light AI Wellness Platform

Products and services

  • QuickScan Strep A AI-powered diagnostic software that analyzes smartphone images of the oropharynx to identify Group A Streptococcus (Strep A) infections at point-of-care. Designed for healthcare providers to differentiate between viral and bacterial pharyngitis, achieving 96.57% accuracy and 100% NPV in pre-FDA validation studies.
  • Light AI Wellness App Direct-to-consumer mobile application for at-home health screening of Strep A, COVID-19, and conjunctivitis using AI algorithms applied to smartphone camera images. Targets families and individuals for home health management without requiring swabs, lab tests, or proprietary hardware.
  • Light AI Digital Clinical Lab Platform Cloud-based AI platform vision combining smartphone cameras with cloud AI to provide quick and accessible diagnosis for multiple conditions. Currently focused on throat conditions, with expansion planned for eye (conjunctivitis) and skin analysis. Requires no swabs, lab tests, or proprietary hardware.

Quantifiable outcome

  • 97% accuracy in differentiating viral vs bacterial pharyngitis (96.57% in some studies)
  • +4 more outcomes

Companies that use Light AI

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Light AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Light AI partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

  • NHC NZ (National Hauora Coalition)coreStrategic or Co-development Partner · 15 June 2026Pilot study partnership with National Hauora Coalition New Zealand for QuickScan Strep A testing in New Zealand healthcare settings to validate clinical performance.
  • ELIQUENT Life SciencescoreImplementation/ SI/ Consulting Partner · 19 February 2025Partnership with ELIQUENT Life Sciences to support bringing Light AI's cutting-edge AI medical technologies to the U.S. market. ELIQUENT provides regulatory consulting and submission support for FDA authorization process.
  • MrBeast / Beast PhilanthropyflagshipStrategic or Co-development Partner · 18 February 2025High-profile partnership to provide AI-powered Strep A testing in Africa. Beast Philanthropy (MrBeast's philanthropic organization) collaborating to deploy Light AI's diagnostic technology in underserved regions for rheumatic heart disease prevention.
  • Commodity Partners Inc.minorGTM or Marketing Partner · 14 February 2025Engagement of investor relations services from Commodity Partners Inc. to provide capital markets and investor relations advisory services under agreement dated February 14, 2025 for CDN$120,000 annual fee.
  • Emergo by ULcoreImplementation/ SI/ Consulting Partner · 7 February 2025Engagement with Emergo by UL for global regulatory submissions support. Provides regulatory consulting services for international market authorization beyond U.S. FDA process.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Light AI competitors and assessment

Company assessment

Direct peers

  • Healthy.io: Healthy.io uses smartphone cameras combined with AI/computer vision to enable at-home urinalysis and chronic kidney disease screening—closely paralleling Light AI's smartphone-camera AI diagnostic model and regulatory pathway.
  • TytoCare: TytoCare delivers AI-assisted remote physical examination and diagnostics via consumer devices for telehealth providers—comparable in delivering AI-enhanced clinical assessments through consumer-grade hardware at the point of care.
  • Visby Medical: Visby Medical develops rapid PCR-based diagnostic tests for infectious diseases including sexual health and respiratory infections—directly competing in the point-of-care infectious disease diagnostic market that Light AI is targeting with QuickScan Strep A.
  • Cue Health: Cue Health produces a connected rapid molecular diagnostic platform for at-home and clinical use, including respiratory infections (COVID-19, influenza)—a direct competitor in consumer/clinical rapid infectious disease diagnostics.
  • ResApp Health: ResApp Health developed AI algorithms to diagnose respiratory conditions (pneumonia, bronchiolitis, COPD) from cough and lung sound recordings—a highly comparable AI-audio/visual diagnostic platform for infectious disease (acquired by Pfizer in 2022).
  • Eko Health: Eko Health combines AI with digital stethoscopes and sensors to detect cardiac and pulmonary conditions—closely parallel to Light AI's model of applying AI to standard hardware for clinical-grade diagnosis.
  • Binx Health: Binx Health provides rapid molecular diagnostics for infectious diseases at point-of-care, including CT/NG testing—directly comparable to Light AI's goal of decentralizing infectious disease testing away from centralized labs.

Broad incumbents

  • Babylon Health: Babylon Health offers a broader AI-driven symptom assessment and triage platform that competes at the diagnostic decision-support layer Light AI targets—though Babylon is a wider digital health incumbent rather than a focused infectious-disease specialist.

Emerging players

  • K Health: K Health combines AI symptom checking with telehealth consultations to deliver remote diagnoses—a comparable AI-driven consumer health diagnostic experience, though focused on primary care rather than specific infectious disease imaging.
  • DreaMed Diabetes (now part of Medtronic): DreaMed developed AI clinical decision support for diabetes management—an adjacent regulated SaMD player demonstrating the AI clinical decision support pathway Light AI is pursuing, though in a different therapeutic area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Light AI social profiles

Digital presence

Light AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Light AI leadership team

Management profile

Number of profiles

Profiles14 records

Light AI funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Light AI M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Light AI

What does Light AI do?

Light AI develops AI-powered diagnostic software that applies machine learning algorithms to smartphone camera images to identify bacterial and viral infections in seconds. The company offers two distinct products: QuickScan Strep A, a clinical diagnostic software for healthcare providers to differentiate Group A Streptococcus infections at point-of-care, and a consumer-facing Wellness App for at-home screening of Strep A, COVID-19, and conjunctivitis. The cloud-based platform requires no swabs, lab tests, or proprietary hardware, leveraging the 4.5 billion existing smartphones globally.

Is Light AI a public or private company?

Light AI is a public company. It is classified as public and is currently operating.

When was Light AI founded?

Light AI was founded in 2015. It employs 11 to 50 people.

Where is Light AI based?

Light AI is headquartered in Vancouver, Canada, in the North America region.

How does Light AI make money?

Three revenue lines are on record. Wellness App Sales are the primary driver. The others are healthcare Provider Licensing and international Regulatory Authorization.

Who are Light AI's main competitors?

Direct peers on record are Healthy.io, TytoCare, Visby Medical, Cue Health, ResApp Health, Eko Health and Binx Health. Babylon Health is listed as a broad incumbent. Emerging players are K Health and DreaMed Diabetes (now part of Medtronic).

Does Light AI have an API?

No public API is recorded for Light AI.

What industry is Light AI in?

Light AI's product category is AI Medical Diagnostics Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACANAE, SaMD – Monitoring, Triage & Risk Stratification Software. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingLight AI Restructures to Cut Monthly Operating Expenditures by About 40%Light AI is restructuring to cut staffing and consulting resources, expected to reduce monthly operating expenditures by about 40%. The overhaul aims to extend cash runway while retaining essential capabilities for QuickScan Strep A development and quality remediation.TradingViewLight AI Inc. (ALGO) Expects Monthly Operating Costs to Fall Approximately 40%Light AI Inc. expects monthly operating costs to fall approximately 40% through staffing and consulting reductions, subject to completion of restructuring and contractual obligations. The company says the measures aim to extend its cash runway, but no baseline expense or quantified runway extension is disclosed.The future of tradingLight AI's Peter Whitehead Resigns as Director and Chief Innovation OfficerLight AI announced on Nov. 6, 2026, that Peter Whitehead resigned as director and chief innovation officer to pursue other opportunities. The resignation was not accompanied by a reason or successor information.TradingViewLight AI Inc. (ALGO) Director and Chief Innovation Officer ResignsPeter Whitehead resigned as director and Chief Innovation Officer of Light AI Inc. to pursue other opportunities. The departure leaves both the board and senior innovation role vacant, with no successor named.TradingViewLight AI Inc. (ALGO) Cuts Q3 Loss to $1.5M; Says More Financing NeededLight AI reported an unaudited Q3 2026 net loss of $1.5M, down from $5.6M a year earlier, with $6.1M cash at September 30. The company expects additional financing within 12 months, and QuickScan development timelines have been affected by remediation.YahooLight AI reports Financial Results for Three and Six Months ended June 30, 2026Light AI Inc. reported a net loss of $1,629,346 for the second quarter of 2026, marking a significant decrease from the $4,025,147 loss in the same period last year. The reduction in losses was primarily driven by substantial cuts in marketing and investor relations expenses, alongside lower research and development costs as the company transitions from initial product development to regulatory testing for its QuickScan™ Strep A software.NewswireLIGHT AI ACHIEVES ISO 13485 AND MDSAP CERTIFICATION, ADVANCING REGULATORY READINESS FOR HEALTH CANADA SUBMISSION OF QUICKSCAN™ SOFTWARE PLATFORMLight AI completed its quality management system audit and received ISO 13485:2016 and MDSAP certification from Intertek. The certification supports its planned Health Canada regulatory submissions for QuickScan and QuickScan Strep A software platforms. The company expects to provide updates on submission timing.NewswireLight AI Appoints DirectorLight AI appointed Dallas Fontaine to its board of directors as nominee of MV Capital LP, following a C$5,000,000 secured convertible debenture unit financing. Fontaine, CEO of Mountain Vista Capital, brings capital markets and technology commercialization experience. The company aims to advance its QuickScan platform toward regulatory approvals and commercialization.TechcouverLight AI Secures Working Capital for Medical Tech with Eye on Clinical TrialLight AI, a Vancouver-based digital healthcare technology company, has completed a $5 million private placement financing from MV Capital to support ISO 13485/QMS audit completion and Health Canada registration submission. The company has also confirmed the initiation of its FDA clinical trial for QuickScan Strep A, an AI-powered diagnostic platform that achieved 97% accuracy in pre-FDA validation studies for differentiating viral and bacterial pharyngitis. The pivotal trial is designed to generate evidence supporting a future submission to the U.S. Food and Drug Administration for marketing authorization as a Class II medical device.